Zoetis (ZTS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 May, 2026Opening remarks and agenda
Meeting commenced virtually with introductions of board members, executive officers, and independent auditors.
Shareholders were informed about voting procedures and access to meeting materials.
The agenda included five formal business items and a Q&A session.
Board and executive committee updates
Twelve director nominees were presented for election to serve one-year terms until the 2027 meeting.
Board recommended voting for all director nominees and for annual advisory votes on executive compensation.
Shareholder proposals
A shareholder proposal to permit action by written consent was presented and supported by its sponsor.
The board recommended voting against the proposal, citing reasons in the proxy statement.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Zoetis
- Q2 2026 revenue flat; U.S. Companion Animal down, Livestock and International segments up; guidance cut.ZTS
Q2 2026 - Strong growth, innovation, and channel expansion offset tariff risks and competitive pressures.ZTS
Stifel Jaws & Paws Conference 2025 - Tariff impacts are managed, innovation and alternative channels drive sustained growth.ZTS
BNP Paribas 2nd Annual Animal Health Day - Above-market growth driven by innovation, strong franchises, and strategic R&D investment.ZTS
Piper Sandler 36th Annual Healthcare Conference - Driving animal health innovation and growth with global scale, R&D, and strong shareholder returns.ZTS
Corporate presentation - Innovation pipeline and global diversification drive growth despite macro and competitive headwinds.ZTS
46th Annual William Blair Growth Stock Conference - 2026 growth guided at 2%-5%, with innovation and targeted promotions offsetting competition.ZTS
Stifel Jaws & Paws Conference 2026 - Q3 2024 delivered 14% operational revenue growth and raised guidance, led by key franchises.ZTS
Q3 2024 - Q1 2025 saw 9% organic revenue growth and raised adjusted EPS guidance to $6.20–$6.30.ZTS
Q1 2025